FIBROGEN Forum: Community User: NOK

FibroGen Reports First Quarter 2021 Financial Results https://www.globenewswire.com/news-release/2021/05/10/2226627/0/en/FibroGen-Reports-First-Quarter-2021-Financial-Results.html • Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis • Total roxadustat net sales in China of $43.5 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca, compared to $29.2 million last quarter • FDA to hold Advisory Committee Meeting on Roxadustat NDA - tentative date July 15, 2021 ...

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy https://www.globenewswire.com/news-release/2021/04/15/2210640/33525/en/FibroGen-Receives-Rare-Pediatric-Disease-Designation-from-the-U-S-FDA-for-Pamrevlumab-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html

FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy https://www.globenewswire.com/news-release/2021/04/12/2208102/33525/en/FibroGen-Receives-Fast-Track-Designation-from-the-U-S-FDA-for-Pamrevlumab-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html

Anschnallen oder guter Einstiegskurs?

https://de.investing.com/news/stock-market-news/fibrogenaktie-crasht-unstimmigkeiten-bei-sicherheitsdaten-2122890 Fibrogen-Aktie crasht: Unstimmigkeiten bei Sicherheitsdaten

Was los hier

🥺🥺🥺

Yeeaah 👍👍👍

*** durch finanz.trends (ohne den Punkt) ersetzen

https://www.finanztrends.de/biotech-aktien-der-taegliche-biotech-puls-2/

gibts auch news auf deutsch?warum absturz

FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results http://www.globenewswire.com/news-release/2021/03/01/2184671/0/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million FDA to hold Advisory Committee Meeting on Roxadustat New Drug Application

FibroGen EPS misses by $0.38, misses on revenue https://seekingalpha.com/news/3667889 • FibroGen (NASDAQ:FGEN): Q4 GAAP EPS of -$0.64 misses by $0.38. • Revenue of $64.99M (+715.4% Y/Y) misses by $35.83M. • Shares -17.3%.

BRIEF-FibroGen Inc Entered Into A Supply Agreement With Astellas Pharma Europe Ltd On Jan. 13 https://pub.webull.com/us/news-html/b6d596de08104c34ac7963f93f2045eb.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en https://m.marketscreener.com/quote/stock/FIBROGEN-INC-18537026/news/FIBROGEN-INC-Entry-into-a-Material-Definitive-Agreement-form-8-K-32286087/

https://seekingalpha.com/article/4396152-fibrogen-roxadustats-u-s-approval-2020-china-sales-and-outsized-growth

FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 https://www.globenewswire.com/news-release/2020/12/22/2149257/0/en/FibroGen-Advances-Phase-3-Clinical-Development-of-Pamrevlumab-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis-with-Initiation-of-ZEPHYRUS-2.html